Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6JCya-Spred1em1flox/Cya
Common Name:
Spred1-flox
Product ID:
S-CKO-17852
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Spred1-flox
Strain ID
CKOCMP-114715-Spred1-B6J-VB
Gene Name
Spred1
Product ID
S-CKO-17852
Gene Alias
5730461F13Rik
Background
C57BL/6JCya
NCBI ID
114715
Modification
Conditional knockout
Chromosome
2
Phenotype
MGI:2150016
Document
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Note
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Spred1em1flox/Cya mice (Catalog S-CKO-17852) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000028829
NCBI RefSeq
NM_033524
Target Region
Exon 2
Size of Effective Region
~1.2 kb
Detailed Document
Click here to download >>
Overview of Gene Research
Spred1, short for Sprouty-related, EVH1 domain-containing protein 1, is a negative regulator of the RAS-MAPK signaling pathway [5,6,7]. It belongs to the Sprouty related protein family and is crucial for normal cellular growth and development, playing a role in downregulating this key signaling cascade that is involved in numerous biological processes such as cell proliferation, differentiation, and survival [5,6,7]. Genetic models, like knockout (KO) mouse models, have been instrumental in studying its function.

In chronic myelogenous leukemia (CML), Spred1 knockout in SCLtTA/BCR-ABL CML mice, whether global or restricted to hematopoietic cells (HSCs) or endothelial cells (ECs), led to the transformation of chronic phase CML into accelerated phase/blast crisis CML. Spred1 KO increased miR-126 in LSKs, expanding leukemic stem cells likely via hyperactivation of the MAPK/ERK pathway, enhancing Bcl-2-dependent oxidative phosphorylation, and driving the transformation [1]. In melanoma, SPRED1 inactivation in human melanoma cell lines and primary zebrafish melanoma conferred resistance to BRAFV600E inhibition by re-activating MAPK activity, and biallelic deletion was seen in a patient with acquired resistance to MAPK-targeted therapy [2]. In acute myeloid leukemia (AML), in vitro experiments using THP-1 cells showed that demethylation of SPRED1 could inhibit cell proliferation and promote differentiation and apoptosis, possibly through the ERK pathway [3]. Also, in AML, decreased SPRED1 expression was associated with lower 2-year progression-free and event-free survival rates in non-acute promyelocytic leukemia patients, and ectopic overexpression of SPRED1 in THP-1 cells led to decreased ERK phosphorylation, apoptosis induction, and reduced cell proliferation [4].

In summary, Spred1 is essential for regulating the RAS-MAPK signaling pathway, which impacts various biological processes. Model-based research, especially KO mouse models, has revealed its significant roles in diseases such as CML, melanoma, and AML. Understanding Spred1's functions provides insights into disease mechanisms and potential therapeutic targets for these malignancies.

References:
1. Qiao, Junjing, Liang, Chen, Zhao, Dandan, Zhang, Bin Amber, Marcucci, Guido. 2021. Spred1 deficit promotes treatment resistance and transformation of chronic phase CML. In Leukemia, 36, 492-506. doi:10.1038/s41375-021-01423-x. https://pubmed.ncbi.nlm.nih.gov/34564700/
2. Ablain, Julien, Liu, Sixue, Moriceau, Gatien, Lo, Roger S, Zon, Leonard I. . SPRED1 deletion confers resistance to MAPK inhibition in melanoma. In The Journal of experimental medicine, 218, . doi:10.1084/jem.20201097. https://pubmed.ncbi.nlm.nih.gov/33306107/
3. Su, Nan, Wang, Yujiao, Lu, Xianglan, Li, Yan, Zhang, Rui. 2022. Methylation of SPRED1: A New Target in Acute Myeloid Leukemia. In Frontiers in oncology, 12, 854192. doi:10.3389/fonc.2022.854192. https://pubmed.ncbi.nlm.nih.gov/35359401/
4. Zhang, Rui, Zhang, Yan, Lu, Xianglan, Yan, Xiaojing, Li, Yan. 2020. SPRED1 Is Downregulated and a Prognostic Biomarker in Adult Acute Myeloid Leukemia. In Frontiers in oncology, 10, 204. doi:10.3389/fonc.2020.00204. https://pubmed.ncbi.nlm.nih.gov/32175275/
5. Brems, Hilde, Pasmant, Eric, Van Minkelen, Rick, Legius, Eric, Messiaen, Ludwine. 2012. Review and update of SPRED1 mutations causing Legius syndrome. In Human mutation, 33, 1538-46. doi:10.1002/humu.22152. https://pubmed.ncbi.nlm.nih.gov/22753041/
6. Brems, Hilde, Legius, Eric. 2013. Legius syndrome, an Update. Molecular pathology of mutations in SPRED1. In The Keio journal of medicine, 62, 107-12. doi:. https://pubmed.ncbi.nlm.nih.gov/24334617/
7. Chelleri, Cristina, Brolatti, Noemi, De Marco, Patrizia, Zara, Federico, Scala, Marcello. 2024. Novel causative variants in Legius syndrome: SPRED1 Genotype spectrum expansion. In American journal of medical genetics. Part A, 194, e63824. doi:10.1002/ajmg.a.63824. https://pubmed.ncbi.nlm.nih.gov/39031930/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest